# The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma

> **NCT03394508** · PHASE2,PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 30 (actual)

## Conditions studied

- Rhinitis
- Asthma
- Allergy

## Interventions

- **DRUG:** ALK Alutard birch or 5-grasses
- **DRUG:** ALK diluent 0,3% human albumin

## Key facts

- **NCT ID:** NCT03394508
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03394508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03394508, "The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03394508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*